171 related articles for article (PubMed ID: 37395564)
1. Impact of Traditional Chinese Medicine on Prognosis of Patients with Hepatocellular Carcinoma: A Retrospective Cohort Study.
Yuan H; Niu Q; Shang X; Zhang L; Li L; Yang H; Gou C; Li J; Li H; Li X
Integr Cancer Ther; 2023; 22():15347354231170536. PubMed ID: 37395564
[TBL] [Abstract][Full Text] [Related]
2. Effects of adjuvant traditional Chinese medicine therapy on long-term survival in patients with hepatocellular carcinoma.
Liu X; Li M; Wang X; Dang Z; Yu L; Wang X; Jiang Y; Yang Z
Phytomedicine; 2019 Sep; 62():152930. PubMed ID: 31128485
[TBL] [Abstract][Full Text] [Related]
3. A Cohort Study to Examine the Use of Chinese Herbal Medicine in Combination With Conventional Therapies for Patients With Hepatocellular Carcinoma in China.
Sun L; Fahey P; Zhu X; Ng W; Chen ZP; Qiu Y; Lai H; Lin J; Lin L
Integr Cancer Ther; 2018 Sep; 17(3):902-911. PubMed ID: 29775121
[TBL] [Abstract][Full Text] [Related]
4. Fuzheng Jiedu Xiaoji formulation inhibits hepatocellular carcinoma progression in patients by targeting the AKT/CyclinD1/p21/p27 pathway.
Yang X; Feng Y; Liu Y; Ye X; Ji X; Sun L; Gao F; Zhang Q; Li Y; Zhu B; Wang X
Phytomedicine; 2021 Jul; 87():153575. PubMed ID: 33984593
[TBL] [Abstract][Full Text] [Related]
5. Huaier granule prevents the recurrence of early-stage hepatocellular carcinoma after thermal ablation: A cohort study.
Wang Z; Yu XL; Zhang J; Cheng ZG; Han ZY; Liu FY; Dou JP; Kong Y; Dong XJ; Zhao QX; Yu J; Liang P; Tang WZ
J Ethnopharmacol; 2021 Dec; 281():114539. PubMed ID: 34428522
[TBL] [Abstract][Full Text] [Related]
6. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
Zhu HF; Feng JK; Xiang YJ; Wang K; Zhou LP; Liu ZH; Cheng YQ; Shi J; Guo WX; Cheng SQ
BMC Cancer; 2023 Jun; 23(1):547. PubMed ID: 37322411
[TBL] [Abstract][Full Text] [Related]
7. A traditional Chinese herbal medicine compound preparation versus interventional therapy after resection of small hepatocellular carcinoma: 22-year follow-up.
Sun Z; Liang ST; Zhai XF; Lang QB; Zhou QH; Yue XQ; He J; Xu J; Zhu Y; Ling CQ
J Tradit Chin Med; 2012 Jun; 32(2):156-63. PubMed ID: 22876437
[TBL] [Abstract][Full Text] [Related]
8. Traditional Chinese Medicine treatment as maintenance therapy in advanced non-small-cell lung cancer: A randomized controlled trial.
Jiang Y; Liu LS; Shen LP; Han ZF; Jian H; Liu JX; Xu L; Li HG; Tian JH; Mao ZJ
Complement Ther Med; 2016 Feb; 24():55-62. PubMed ID: 26860802
[TBL] [Abstract][Full Text] [Related]
9. Clinical study of hepatectomy combined with Jianpi Huayu Therapy for hepatocellular carcinoma.
Zhong C; Li HD; Liu DY; Xu FB; Wu J; Lin XM; Guo RP
Asian Pac J Cancer Prev; 2014; 15(14):5951-7. PubMed ID: 25081728
[TBL] [Abstract][Full Text] [Related]
10. Study on the anti-tumor mechanism related to immune microenvironment of Bombyx Batryticatus on viral and non-viral infections of hepatocellular carcinoma.
Yuan L; Bing Z; Han J; An X; Liu X; Li R; Wang C; Sun X; Yang L; Yang K
Biomed Pharmacother; 2020 Apr; 124():109838. PubMed ID: 31981943
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of traditional herbal medicine versus transcatheter arterial chemoembolization in postsurgical patients with hepatocellular carcinoma: A retrospective study.
Xu X; Chen R; Chen Q; An K; Ding L; Zhang L; Wang F; Deng Y
Complement Ther Clin Pract; 2021 May; 43():101359. PubMed ID: 33711747
[TBL] [Abstract][Full Text] [Related]
12. Survival outcomes of hepatectomy for stage B Hepatocellular carcinoma in the BCLC classification.
Kamiyama T; Orimo T; Wakayama K; Shimada S; Nagatsu A; Yokoo H; Kamachi H; Yamashita K; Shimamura T; Taketomi A
World J Surg Oncol; 2017 Aug; 15(1):156. PubMed ID: 28830473
[TBL] [Abstract][Full Text] [Related]
13. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
[TBL] [Abstract][Full Text] [Related]
14. Overall survival and toxicity of Y90 radioembolization for hepatocellular carcinoma patients in Barcelona Clinic Liver Cancer stage C (BCLC-C).
Goswami P; Adeniran OR; K Frantz S; Matsuoka L; Du L; Gandhi RT; Collins ZS; Matrana MR; Petroziello M; Brower JS; Sze DY; Kennedy AS; Golzarian J; Wang EA; Brown DB
BMC Gastroenterol; 2022 Nov; 22(1):467. PubMed ID: 36396989
[TBL] [Abstract][Full Text] [Related]
15. Integrating Chinese and Western medicines reduced the incidence of hepatocellular carcinoma in patients with diabetes mellitus: A Taiwanese population-based cohort study.
Lu HL; Su YC; Lin MC; Sun MF; Huang ST
Complement Ther Med; 2020 Mar; 49():102332. PubMed ID: 32147062
[TBL] [Abstract][Full Text] [Related]
16. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
Oncologist; 2012; 17(1):13. PubMed ID: 22210086
[TBL] [Abstract][Full Text] [Related]
18.
Liu Y; Li Y; Wang X; Huang Y; Zhang Q; Shi K; Ran C; Hou J; Wang X
J Altern Complement Med; 2020 Oct; 26(10):956-965. PubMed ID: 32614605
[No Abstract] [Full Text] [Related]
19. Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience.
Abdel-Rahman O; Abdelwahab M; Shaker M; Abdelwahab S; Elbassiony M; Ellithy M
J Egypt Natl Canc Inst; 2014 Mar; 26(1):9-13. PubMed ID: 24565677
[TBL] [Abstract][Full Text] [Related]
20. Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications.
Sun X; Zhang Q; Mei J; Yang Z; Chen M; Liang T
BMC Cancer; 2022 Mar; 22(1):293. PubMed ID: 35305593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
